Z-LLY-FMK
Need Assistance?
  • US & Canada:
    +
  • UK: +

Z-LLY-FMK

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Z-LLY-FMK is a cell-permeant and irreversible calpain inhibitor that is selective for calpain II, and also exhibits inhibitory effect against cathepsin L. It was shown to suppress hepatocyte apoptosis after bile duct ligation in rat.

Category
Peptide Inhibitors
Catalog number
BAT-010363
CAS number
133410-84-1
Molecular Formula
C30H40FN3O6
Molecular Weight
557.66
Z-LLY-FMK
IUPAC Name
benzyl N-[(2S)-1-[[(2S)-1-[[(2S)-4-fluoro-1-(4-hydroxyphenyl)-3-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate
Synonyms
Calpain Inhibitor IV; Z-Leu-Leu-Tyr-FMK; Z-Leu-Leu-Tyr-Fluoromethylketone; N-[(benzyloxy)carbonyl]-L-leucyl-N-[(1S)-3-fluoro-1-(4-hydroxybenzyl)-2-oxopropyl]-L-leucinamide
Appearance
White to Pale Yellow Solid
Purity
≥95%
Density
1.176±0.06 g/cm3 (Predicted)
Boiling Point
800.9±65.0°C (Predicted)
Sequence
Cbz-Leu-Leu-Tyr-FMK
Storage
Store at -20°C
Solubility
Soluble in DMSO (25 mg/mL)
InChI
InChI=1S/C30H40FN3O6/c1-19(2)14-25(28(37)32-24(27(36)17-31)16-21-10-12-23(35)13-11-21)33-29(38)26(15-20(3)4)34-30(39)40-18-22-8-6-5-7-9-22/h5-13,19-20,24-26,35H,14-18H2,1-4H3,(H,32,37)(H,33,38)(H,34,39)/t24-,25-,26-/m0/s1
InChI Key
JCRSHQCFRMCMOC-GSDHBNRESA-N
Canonical SMILES
CC(C)CC(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)CF)NC(=O)C(CC(C)C)NC(=O)OCC2=CC=CC=C2
1. Z-LLY-FMK attenuates intestinal apoptosis after bile duct ligation in rats
Hsin-Tsung Ho, Hock-Liew Eng, Shyr-Ming Sheen-Chen Dig Dis Sci . 2009 Nov;54(11):2357-61. doi: 10.1007/s10620-008-0652-9.
Apoptosis is an important process in a wide variety of different biological systems. In addition to caspases, recently, calpains, another family of proteases, have been found to be involved in apoptosis of many cell systems. This study is designed with the aims to evaluate the possible effect of Z-LLY-FMK (a calpain inhibitor) on intestine apoptosis after bile duct ligation in rats. Male Sprague-Dawley rats weighing 250-300 g were randomized to five groups (n = 6 in each group). Group 1 (CONTROL: C) underwent Sham operation and were simultaneously treated with the same amount of normal saline. Group 2 (CONTROL with DMSO: CDMSO) underwent Sham operation and were simultaneously treated with the same amount of dimethylsulfoxide (DMSO). Group 3 (Obstructive jaundice: OB) underwent common bile duct ligation without any other manipulation. Group 4 (Obstructive jaundice with Z-LLY-FMK: OBZLLY) underwent common bile duct ligation and were simultaneously treated with Z-LLY-FMK (dissolved in DMSO). Group 5 (Obstructive jaundice with ZFA-FMK: OBZFA) underwent common bile duct ligation and were simultaneously treated with ZFA-FMK (dissolved in DMSO). After 3 days, intestine tissue was harvested for apoptosis measurements. There was no significant difference between Sham operation group (C) and Sham operation with DMSO group (CDMSO) either in jejunum (P = 0.924) or in ileum (P = 0.996). When compared to Sham operation group (C), increased intestine apoptosis occurred in either jejunum (P < 0.001) or in ileum (P < 0.001) after common bile duct ligation (OB). After administration of Z-LLY-FMK (OBZLLY), the increased intestine apoptosis after common bile duct ligation (OB) was significantly diminished either in jejunum or in ileum (P < 0.001 and P < 0.001). Moreover, administration of ZFA (OBZFA) failed to show the same phenomenon in either jejunum (P = 0.993) or ileum (P = 0.485). There was a significant difference in intestine apoptosis in either jejunum (P < 0.001) or in ileum (P < 0.001) between OBZLLY group and OBZFA group. Significantly increased intestine apoptosis occurred after common bile duct ligation. The administration of Z-LLY-FMK could effectively diminish the intestine apoptosis after common bile duct ligation, whereas the administration of ZFA-FMK failed to show the same effect.
2. Z-LLY-FMK can attenuate hepatocyte apoptosis after bile duct ligation in rat
Hsin-Tsung Ho, Hock-Liew Eng, Kuo-Sheng Hung, Shyr-Ming Sheen-Chen Dig Dis Sci . 2008 Nov;53(11):2975-9. doi: 10.1007/s10620-008-0306-y.
Background:Cholestasis leading to retention and accumulation of toxic hydrophobic bile salts within hepatocytes may cause hepatocyte toxicity by inducing apoptosis. Calpains have been found to be involved in apoptosis of many cell systems. This study is designed with the aim of evaluating the possible effect of Z-LLY-FMK (a calpain inhibitor) on hepatocyte apoptosis after bile duct ligation in rat.Materials and methods:Male Sprague-Dawley rats were randomized to five groups. Group 1 (C) underwent sham operation. Group 2 (CDMSO) underwent Sham operation and simultaneous treatment with dimethylsulfoxide (DMSO). Group 3 (OB) underwent common bile duct ligation. Group 4 (OBZLLY) underwent common bile duct ligation and simultaneous treatment with Z-LLY-FMK. Group 5 (OBZFA) underwent common bile duct ligation and simultaneous treatment with ZFA-FMK. After 3 days, liver tissue was harvested for histopathologic analysis and apoptosis measurements.Results:When compared with sham operation groups, increased hepatocyte apoptosis (P < 0.001) and ductular proliferation (P < 0.001) occurred after common bile duct ligation. Following administration of Z-LLY-FMK, the increased hepatocyte apoptosis and ductular proliferation after common bile duct ligation were significantly diminished (P < 0.001 and P < 0.001). Moreover, administration of ZFA failed to show the same phenomenon (P = 0.9 and 0.987).Conclusion:Significantly increased hepatocyte apoptosis and ductular proliferation occurred after common bile duct ligation. The administration of Z-LLY-FMK could effectively diminish the hepatocyte apoptosis and ductular proliferation after common bile duct ligation, whereas the administration of ZFA-FMK failed to show the same effect.
3. Cysteine proteinase inhibitors in murine cysticercosis
Meredith Welch, A Clinton White Jr, Raymond T Damian, Amr Ghaleb, Jamil Talhouk, Jorge Morales-Montor, Salman Baig, Rupal Thazhath Antimicrob Agents Chemother . 2006 Aug;50(8):2886-8. doi: 10.1128/AAC.01060-05.
We explored the prophylactic efficacies of two novel protease inhibitors in murine cysticercosis. Our results demonstrated a 95% and 80% reduction in parasite burden for mice injected with Z-LLL-FMK and Z-LLY-FMK, respectively. Further studies are merited on the role of cysteine proteinase inhibitors in treatment of cysticercosis.
Online Inquiry
Verification code
Inquiry Basket